Fibro Foundation

"I know there is a cure out there and I hope we find it in my lifetime, 
but if we don't... you have to find it."
                                                              - Tucker Davis 1981-2010

Newly diagnosed? Click here.

In 2008, when Tucker Davis (age 26) was diagnosed with fibrolamellar hepatocellular carcinoma (FHC), he founded the Fibrolamellar Cancer Foundation (FCF) with the hope of finding a cure for this often fatal disease. Because the incidence of FHC was so rare, little research had been conducted at that time. FCF has helped change that.

FCF's mission is three-fold:

  1. Find a cure and treatment options

  2. Raise awareness of this disease

  3. Connect and support the fibrolamellar community of patients and their families

FCF is an IRS approved 501 (c) (3) tax deductible public charity. 100% of net donations go towards research. All FCF's overhead and administrative costs are paid by the Charles A. and Marna Davis Foundation and Stone Point Capital.
 

~~~~ Featured FCF News ~~~~
 

ASCO, the American Society of Clinical Oncology, is supported by the Conquer Cancer Foundation.  The Conquer Cancer Foundation (CCF) was created by the world’s foremost cancer doctors of the American Society of Clinical Oncology (ASCO) to seek dramatic advances in the prevention, treatment and cures of all types of cancer. 

FCF is supporting a Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) in FL-HCC. The Conquer Cancer Foundation is currently accepting YIA applications and encourages eligible physicians conducting research on FL-HCC to submit an application. The submission deadline is September 24, 2015. Eligibility criteria and application instructions are available online.

ASCO Connection, the professional networking site for ASCO's community is broadly promoting FCF's funding of this award with an extensive article on FCF and the YIA:  

Apply Today for Conquer Cancer Foundation Young Investigator Award in Fibrolamellar Hepatocellular Carcinoma 

John Hopper, Executive Director of FCF indicates that the award will encourage someone early in their career to learn about FL-HCC, focus on it, and give them the opportunity to collaborate with a senior researcher. He urges young investigators to take a “deep look” at FL-HCC, and hopes that young minds coming out of medical and fellowship programs may see this as a way to make a difference in people’s lives.

FCF is especially pleased to be working with the Conquer Cancer Foundation and ASCO to generate additional awareness about this disease through the YIA program, which reaches a very large global population. 

“While fibrolamellar hepatocellular carcinoma is rare, it is relatively simple, with few mutations noted, occurring in apparently healthy young people with a generally predictable natural history, so many of the typical confounders are not present,” said Alan P. Venook, MD, of the University of California, San Francisco, an ASCO member who serves on the FCF Scientific Advisory Board. “The bonus is that it is not unlikely that a discovery in a rare cancer may open up other areas of exploration in common cancers."

 

Previously Featured stories archived here.
 

Photos in header:  (Above, left) Tucker Davis, (Above, right) Joshua Honeyman, former Rockefeller University Fellow, at work in Dr. Simon’s research lab in NYC 

 

CONTACT USJOIN